Clinical trials: Pollen Allergy
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Healthy
Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies
In this randomized, double-blind, placebo-controlled study, participants with seasonal allergies will receive a daily probiotic or placebo for 8 weeks.
- Trial name
- JEN (NCT02349711)
- Testing
- Probiotic mixture
- Where
- United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- University of Florida
Seasonal Allergic Rhinitis
Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients
The purpose of this study was to demonstrate the efficacy and safety of omalizumab compared with placebo, on top of SoC (anti-histamine and nasal corticosteroid) in adult and adolescent patients with severe Japanese cedar…
- Trial name
- NCT03369704
- Testing
- Omalizumab
- Where
- 22 sites in Japan
- Volunteers
- 337 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Seasonal
A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
This study compared the efficacy and safety of a generic mometasone nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis.
- Trial name
- NCT01038427
- Testing
- Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray
- Where
- 8 sites in United States
- Volunteers
- 795 people
- Sponsor
- Sandoz
Seasonal Allergic Rhinitis (SAR)
Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Study to evaluate the efficacy, safety and tolerability of GSP 301 nasal spray (NS) compared with placebo NS in pediatric subjects (aged 6 to under 12 years) with Seasonal Allergic Rhinitis (SAR).
- Trial name
- GSP 301-305 (NCT03463031)
- Testing
- GSP 301 NS
- Where
- 32 sites in United States
- Volunteers
- 446 people
- Sponsor
- Glenmark Specialty S.A.
Seasonal Allergic Rhinitis
Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)
This study will evaluate the efficacy and safety of montelukast (MK-0476) in the treatment of Japanese pediatric participants with seasonal allergic rhinitis (SAR).
- Trial name
- NCT01857063
- Testing
- Montelukast
- Volunteers
- 220 people
- Sponsor
- Organon and Co
Rhinitis, Allergic, Perennial and Seasonal
A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
This study will be a randomised, double blind, placebo controlled, 3-way, incomplete block crossover study to evaluate the effect of single and repeat doses of levocabastine, FF, placebo and a FDC of FF/levocabastine…
- Trial name
- NCT01957202
- Testing
- FF/levocabastine, FF, levocabastine
- Where
- Austria
- Volunteers
- 71 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the…
- Trial name
- NCT00562120
- Testing
- Allegra, Allegra-D, PF-03654746
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Allergic Conjunctivitis
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.
- Trial name
- NCT01134328
- Testing
- AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Aciex Therapeutics, Inc.
Allergic Rhinitis
Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
About 45 million people in Europe have allergic rhinitis (hay fever) - inflammation of the nasal passages causing sneezing, runny nose, nasal congestion, itching and tearing of the eyes.
- Trial name
- Pollen+ (NCT02005627)
- Testing
- Grazax
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Seasonal Allergic Rhinitis
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
This is a 2-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11…
- Trial name
- NCT01458275
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 66 sites in United States
- Volunteers
- 847 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seasonal Allergic Rhinitis
Vitamin D Plus Fluticasone Propionate
The objectives of this study would be to see if the addition of vitamin D to fluticasone propionate provides greater symptomatic relief in patients with seasonal allergic rhinitis compared to fluticasone propionate treatment…
- Trial name
- NCT01103934
- Testing
- Vitamin D3, Fluticasone Propionate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Seasonal Allergic Rhinitis
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
This clinical research study will evaluate the safety and effectiveness of two doses of an investigational medication (ciclesonide nasal aerosol) for the treatment of subjects with of seasonal allergic rhinitis (SAR).
- Trial name
- NCT01010971
- Testing
- Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg
- Where
- 7 sites in United States
- Volunteers
- 671 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis
A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)
The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and Fexofenadine) in a model of seasonal allergic rhinitis (SAR).
- Trial name
- NCT01469234
- Testing
- loratadine, fexofenadine
- Volunteers
- 255 people
- Sponsor
- Bayer
Immunologic Desensitization
Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy
The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
- Trial name
- NCT02676765
- Testing
- allergen extract tablet
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Rhinitis
Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis
The hypothesis is that treating hay fever patients who had daytime sleepiness and slowed thinking because of the hay fever will improve when treated with an effective anti-hay fever medication, an intranasal steroid, that is will…
- Trial name
- NCT00997620
- Testing
- Fluticasone furoate Nasal Spray 110 mcg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Western Sky Medical Research
Influenza Infection
Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Background: The flu is a common viral infection that can be deadly for certain people. Vaccines against flu have been developed to teach the body to prevent or fight the infection.
- Trial name
- NCT03814720
- Testing
- VRC-FLUNPF099-00-VP (H1ssF_3928)
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Seasonal Allergic Rhinitis, Hayfever
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.
- Trial name
- NCT00854360
- Testing
- Beclomethasone dipropionate HFA Nasal Aerosol
- Where
- 26 sites in United States
- Volunteers
- 487 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.